Gardner F H, Helmer R E
JAMA. 1980 Jan 4;243(1):35-7. doi: 10.1001/jama.243.1.35.
The bleeding complications of some forms of thrombocytopenia are difficult to control. Many patients become refractory to platelet transfusions even when HLA-matched. We have successfully used aminocaproic acid to control bleeding in 13 patients with amegakaryocytic thrombocytopenia. Four patients receiving long-term therapy with this drug had striking reductions in the number of platelet transfusions required for capillary bleeding. No adverse effects have been noted save for orthostatic hypotension, which is ameliorated by a reduction in dosage. Quantitative platelet function changes have been impossible to demonstrate, but no changes were noted in four patients with normal platelet counts who were receiving high-dose aminocaproic acid for treatment of subarachnoid hemorrhage. Aminocaproic acid has proved to be a valuable agent in the management of patients with amegakaryocytic thrombocytopenia, especially in decreasing the need for platelet transfusions.
某些形式的血小板减少症的出血并发症难以控制。许多患者即使接受了 HLA 配型的血小板输注，仍会变得难治。我们已成功使用氨基己酸控制 13 例无巨核细胞性血小板减少症患者的出血。4 例接受该药物长期治疗的患者，毛细血管出血所需的血小板输注次数显著减少。除体位性低血压外，未观察到不良反应，减少剂量可改善该症状。尽管无法证明血小板功能有定量变化，但 4 例血小板计数正常、因蛛网膜下腔出血接受高剂量氨基己酸治疗的患者未出现变化。氨基己酸已被证明是治疗无巨核细胞性血小板减少症患者的一种有价值的药物，尤其是在减少血小板输注需求方面。
